The FY 2020 report was sent to the FDA from the House, explaining and demanding the FDA, a need to foster and install certain improvements so as to effectively stimulate the nation's statutory regulation in compliance with the new changes with effect from latest 2020.

The committee has also raised other issues that criticized the FDA for a development gap in the cancer therapies. The committee, on the other hand, has funded an additional amount of $ 5 Million for Oncology Centre of Excellence, hoping to mend the gap in the regulatory reforms.